• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

血红蛋白纳米团簇介导的低氧肿瘤微环境中 KPNA4 的调控增强了肝癌的光动力治疗。

Hemoglobin nanoclusters-mediated regulation of KPNA4 in hypoxic tumor microenvironment enhances photodynamic therapy in hepatocellular carcinoma.

机构信息

Department of Anesthesiology, The First Hospital of China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang, 110001, Liaoning Province, China.

Department of breast surgery, The First Hospital of China Medical University, Shenyang, 110001, Liaoning Province, China.

出版信息

J Nanobiotechnology. 2024 Aug 9;22(1):473. doi: 10.1186/s12951-024-02717-9.

DOI:10.1186/s12951-024-02717-9
PMID:39135024
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11318167/
Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) is a highly malignant tumor known for its hypoxic environment, which contributes to resistance against the anticancer drug Sorafenib (SF). Addressing SF resistance in HCC requires innovative strategies to improve tumor oxygenation and effectively deliver therapeutics.

RESULTS

In our study, we explored the role of KPNA4 in mediating hypoxia-induced SF resistance in HCC. We developed hemoglobin nanoclusters (Hb-NCs) capable of carrying oxygen, loaded with indocyanine green (ICG) and SF, named HPRG@SF. In vitro, HPRG@SF targeted HCC cells, alleviated hypoxia, suppressed KPNA4 expression, and enhanced the cytotoxicity of PDT against hypoxic, SF-resistant HCC cells. In vivo experiments supported these findings, showing that HPRG@SF effectively improved the oxygenation within the tumor microenvironment and countered SF resistance through combined photodynamic therapy (PDT).

CONCLUSION

The combination of Hb-NCs with ICG and SF, forming HPRG@SF, presents a potent strategy to overcome drug resistance in hepatocellular carcinoma by improving hypoxia and employing PDT. This approach not only targets the hypoxic conditions that underlie resistance but also provides a synergistic anticancer effect, highlighting its potential for clinical applications in treating resistant HCC.

摘要

背景

肝细胞癌 (HCC) 是一种高度恶性肿瘤，以其缺氧环境为特征，这导致其对抗癌药物索拉非尼 (SF) 产生耐药性。解决 HCC 中的 SF 耐药性需要创新策略来改善肿瘤氧合并有效输送治疗药物。

结果

在我们的研究中，我们探讨了 KPNA4 在介导 HCC 中缺氧诱导的 SF 耐药性中的作用。我们开发了能够携带氧气的血红蛋白纳米簇 (Hb-NCs)，并将其与吲哚菁绿 (ICG) 和 SF 负载，命名为 HPRG@SF。在体外，HPRG@SF 靶向 HCC 细胞，减轻缺氧，抑制 KPNA4 表达，并增强 PDT 对缺氧、SF 耐药 HCC 细胞的细胞毒性。体内实验支持了这些发现，表明 HPRG@SF 通过联合光动力疗法 (PDT) 有效改善了肿瘤微环境中的氧合作用，并克服了 SF 耐药性。

结论

将 Hb-NCs 与 ICG 和 SF 结合形成 HPRG@SF，提出了一种通过改善缺氧和利用 PDT 来克服肝细胞癌药物耐药性的有效策略。这种方法不仅针对耐药性的缺氧条件，而且还提供了协同的抗癌作用，突出了其在治疗耐药性 HCC 中的临床应用潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/79e2e37c57dc/12951_2024_2717_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/302ae4964f54/12951_2024_2717_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/e06303c3e47c/12951_2024_2717_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/a0980e1c06f1/12951_2024_2717_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/1449cff30339/12951_2024_2717_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/29b7995a4a3f/12951_2024_2717_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/c6915c99a0c4/12951_2024_2717_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/4385a7f25e4b/12951_2024_2717_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/4d88e62d83c1/12951_2024_2717_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/79e2e37c57dc/12951_2024_2717_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/302ae4964f54/12951_2024_2717_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/e06303c3e47c/12951_2024_2717_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/a0980e1c06f1/12951_2024_2717_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/1449cff30339/12951_2024_2717_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/29b7995a4a3f/12951_2024_2717_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/c6915c99a0c4/12951_2024_2717_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/4385a7f25e4b/12951_2024_2717_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/4d88e62d83c1/12951_2024_2717_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0810/11318167/79e2e37c57dc/12951_2024_2717_Fig9_HTML.jpg

相似文献

1
Hemoglobin nanoclusters-mediated regulation of KPNA4 in hypoxic tumor microenvironment enhances photodynamic therapy in hepatocellular carcinoma.血红蛋白纳米团簇介导的低氧肿瘤微环境中 KPNA4 的调控增强了肝癌的光动力治疗。
J Nanobiotechnology. 2024 Aug 9;22(1):473. doi: 10.1186/s12951-024-02717-9.
2
Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.缺氧介导的索拉非尼耐药可以通过 EF24 克服，EF24 通过 Von Hippel-Lindau 肿瘤抑制因子依赖性 HIF-1α 抑制在肝细胞癌中发挥作用。
Hepatology. 2013 May;57(5):1847-57. doi: 10.1002/hep.26224. Epub 2013 Mar 14.
3
Synergistic effects of concurrent photodynamic therapy with indocyanine green and chemotherapy in hepatocellular carcinoma cell lines and mouse models.吲哚菁绿与化疗同步进行光动力疗法对肝癌细胞系和小鼠模型的协同作用。
J Photochem Photobiol B. 2023 Feb;239:112642. doi: 10.1016/j.jphotobiol.2022.112642. Epub 2022 Dec 29.
4
Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment.通过多功能纳米粒子共递送獐牙菜苦苷和索拉非尼，通过重编程肿瘤缺氧微环境来对抗肝癌的耐药性。
Drug Deliv. 2019 Dec;26(1):1080-1091. doi: 10.1080/10717544.2019.1654040.
5
Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na/K-ATPase activity and hypoxia-inducible pathways.焦磷酸氧钒钠通过抑制 Na/K-ATP 酶活性和低氧诱导通路克服肝癌细胞对索拉非尼的耐药性。
Sci Rep. 2018 Jun 26;8(1):9706. doi: 10.1038/s41598-018-28010-y.
6
SOD1 inhibition enhances sorafenib efficacy in HBV-related hepatocellular carcinoma by modulating PI3K/Akt/mTOR pathway and ROS-mediated cell death.SOD1 抑制通过调节 PI3K/Akt/mTOR 通路和 ROS 介导的细胞死亡增强索拉非尼在 HBV 相关肝细胞癌中的疗效。
J Cell Mol Med. 2024 Jul;28(14):e18533. doi: 10.1111/jcmm.18533.
7
Periostin contributes to arsenic trioxide resistance in hepatocellular carcinoma cells under hypoxia.骨膜蛋白在缺氧条件下有助于肝癌细胞对三氧化二砷产生抗性。
Biomed Pharmacother. 2017 Apr;88:342-348. doi: 10.1016/j.biopha.2017.01.052. Epub 2017 Jan 21.
8
Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma.新型 STAT3 寡核苷酸化合物抑制肝癌生长并克服对索拉非尼的获得性耐药。
Acta Pharmacol Sin. 2024 Aug;45(8):1701-1714. doi: 10.1038/s41401-024-01261-4. Epub 2024 Apr 12.
9
DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.DNMT3b/OCT4 表达通过 IL-6/STAT3 调控赋予肝癌索拉非尼耐药和不良预后。
J Exp Clin Cancer Res. 2019 Nov 26;38(1):474. doi: 10.1186/s13046-019-1442-2.
10
Synchronous delivery of oxygen and photosensitizer for alleviation of hypoxia tumor microenvironment and dramatically enhanced photodynamic therapy.同步递送氧和光敏剂以缓解缺氧肿瘤微环境并显著增强光动力疗法。
Drug Deliv. 2018 Nov;25(1):585-599. doi: 10.1080/10717544.2018.1435751.

本文引用的文献

1
pH-Responsive Sorafenib/Iron-Co-Loaded Mesoporous Polydopamine Nanoparticles for Synergistic Ferroptosis and Photothermal Therapy.pH 响应性索拉非尼/铁共负载介孔聚多巴胺纳米粒子用于协同铁死亡和光热治疗。
Biomacromolecules. 2024 Jan 8;25(1):522-531. doi: 10.1021/acs.biomac.3c01173. Epub 2023 Dec 12.
2
RNA helicase DDX5 modulates sorafenib sensitivity in hepatocellular carcinoma via the Wnt/β-catenin-ferroptosis axis.RNA 解旋酶 DDX5 通过 Wnt/β-catenin-铁死亡轴调节肝癌对索拉非尼的敏感性。
Cell Death Dis. 2023 Nov 30;14(11):786. doi: 10.1038/s41419-023-06302-0.
3
Integrated single-cell transcriptomics reveals the hypoxia-induced inflammation-cancer transformation in NASH-derived hepatocellular carcinoma.
整合单细胞转录组学揭示了 NASH 衍生的肝细胞癌中缺氧诱导的炎症-癌症转化。
Cell Prolif. 2024 Apr;57(4):e13576. doi: 10.1111/cpr.13576. Epub 2023 Nov 22.
4
Roles of long non-coding RNAs in digestive tract cancer and their clinical application.长链非编码 RNA 在消化道肿瘤中的作用及其临床应用。
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023 Aug 25;52(4):451-459. doi: 10.3724/zdxbyxb-2023-0169.
5
Hyperthermia-triggered biomimetic bubble nanomachines.热触发仿生泡囊纳米机器。
Nat Commun. 2023 Aug 11;14(1):4867. doi: 10.1038/s41467-023-40474-9.
6
Fe-binding transferrin nanovesicles encapsulating sorafenib induce ferroptosis in hepatocellular carcinoma.包裹索拉非尼的铁结合转铁蛋白纳米囊泡可诱导肝癌细胞发生铁死亡。
Biomater Res. 2023 Jul 1;27(1):63. doi: 10.1186/s40824-023-00401-x.
7
Transcription factor glucocorticoid modulatory element-binding protein 1 promotes hepatocellular carcinoma progression by activating Yes-associate protein 1.转录因子糖皮质激素调节元件结合蛋白1通过激活Yes相关蛋白1促进肝细胞癌进展。
World J Gastrointest Oncol. 2023 Jun 15;15(6):988-1004. doi: 10.4251/wjgo.v15.i6.988.
8
Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation.长链非编码 RNA DUXAP8 的缺失协同增强索拉非尼诱导的肝细胞癌中铁死亡通过 SLC7A11 的去棕榈酰化作用。
Clin Transl Med. 2023 Jun;13(6):e1300. doi: 10.1002/ctm2.1300.
9
Bioinformatics Identification of Regulatory Genes and Mechanism Related to Hypoxia-Induced PD-L1 Inhibitor Resistance in Hepatocellular Carcinoma.生物信息学鉴定与肝细胞癌缺氧诱导的 PD-L1 抑制剂耐药相关的调控基因及机制
Int J Mol Sci. 2023 May 13;24(10):8720. doi: 10.3390/ijms24108720.
10
Hemoglobin-stabilized gold nanoclusters displaying oxygen transport ability, self-antioxidation, auto-fluorescence properties and long-term storage potential.血红蛋白稳定的金纳米团簇具有氧运输能力、自抗氧化性、自发荧光特性以及长期储存潜力。
RSC Adv. 2023 May 23;13(23):15540-15553. doi: 10.1039/d3ra00689a. eCollection 2023 May 22.